4 research outputs found

    The Discussion between Leonardo Messinese and Emanuele Severino in View of a Rigorousization of Classical Metaphysics

    Get PDF
    This essay focusses on the proposal for the rigorousization of classical metaphysics that has been put forward by Leonardo Messinese, presenting his critical dialogue with Emanuele Severino concerning the originary truth of the being and its implications for the future of entities. The purpose of this paper is to solicit the continuation of the dialogue between Messinese and Severino, after having highlighted the reasons that lead Messinese to consider only partially convincing the solution provided by Severino about the complete understanding of the «variation» of the experience, which led him to re‐propose the «Principle of creation»

    Thauma: Pain or Wonder? Considerations Starting from Emanuele Severino and Martin Heidegger

    No full text
    The topic of evil, variously understood, constitutes a fundamental object of questioning and problematicity, so much so that the Italian philosopher Emanuele Severino believes that the thauma from which philosophical research traditionally begins means precisely “anguished pain”, caused, in the last resort, from the becoming of entities. This article intends, first of all, to evaluate the argumentative cogency of the Severinian interpretation in reference to this/of this question and then, move on to analyze some of the writings in which Martin Heidegger deals with the same theme/subject: even the German philosopher has in fact provided interesting considerations that can be profitably used to grasp the most appropriate way of understanding this concept. The question that arises, in fact, is not purely terminological, but involves the same intonation that characterizes the philosophical question and the starting point from which it originates. From the comparison between the two philosophers, in addition to some interpretative limits that seem to be found in both, some significant convergences will emerge, at least in relation to the role that emotions play within the philosophical investigation

    Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

    No full text
    Background: Hypertension management in older patients represents a challenge, particularly when hospitalized. Objective: The objective of this study is to investigate the determinants and related outcomes of antihypertensive drug prescription in a cohort of older hospitalized patients. Methods: A total of 5671 patients from REPOSI (a prospective multicentre observational register of older Italian in-patients from internal medicine or geriatric wards) were considered; 4377 (77.2%) were hypertensive. Minimum treatment (MT) for hypertension was defined according to the 2018 ESC guidelines [an angiotensin-converting-enzyme-inhibitor (ACE-I) or an angiotensin-receptor-blocker (ARB) with a calcium-channel-blocker (CCB) and/or a thiazide diuretic; if >80 years old, an ACE-I or ARB or CCB or thiazide diuretic]. Determinants of MT discontinuation at discharge were assessed. Study outcomes were any cause rehospitalization/all cause death, all-cause death, cardiovascular (CV) hospitalization/death, CV death, non-CV death, evaluated according to the presence of MT at discharge. Results: Hypertensive patients were older than normotensives, with a more impaired functional status, higher burden of comorbidity and polypharmacy. A total of 2233 patients were on MT at admission, 1766 were on MT at discharge. Discontinuation of MT was associated with the presence of comorbidities (lower odds for diabetes, higher odds for chronic kidney disease and dementia). An adjusted multivariable logistic regression analysis showed that MT for hypertension at discharge was associated with lower risk of all-cause death, all-cause death/hospitalization, CV death, CV death/hospitalization and non-CV death. Conclusions: Guidelines-suggested MT for hypertension at discharge is associated with a lower risk of adverse clinical outcomes. Nevertheless, changes in antihypertensive treatment still occur in a significant proportion of older hospitalized patients

    Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

    No full text
    corecore